Positron emission tomography (PET) using 6-[F-18]fluoro-L-dihydroxyphenylalanine (F-18-dopa) has an excellent sensitivity to detect carcinoid tumour lesions. F-18-dopa tumour uptake and the levels of biochemical tumour markers are mediated by tumour endocrine metabolic activity. We evaluated whether total F-18-dopa tumour uptake on PET, defined as whole-body metabolic tumour burden (WBMTB), reflects tumour load per patient, as measured with tumour markers.
Seventy-seven consecutive carcinoid patients who underwent an F-18-dopa PET scan in two previously published studies were analysed. For all tumour lesions mean standardised uptake values (SUVs) at 40% of the maximal SUV and tumour volume on F-18-dopa PET were determined and multiplied to calculate a metabolic burden per lesion. WBMTB was the sum of the metabolic burden of all individual lesions per patient. The 24-h urinary serotonin, urine and plasma 5-hydroxindoleacetic acid (5-HIAA), catecholamines (nor)epinephrine, dopamine and their metabolites, measured in urine and plasma, and serum chromogranin A served as tumour markers.
All but 1 were evaluable for WBMTB; 74 patients had metastatic disease. F-18-dopa PET detected 979 lesions. SUVmax on F-18-dopa PET varied up to 29-fold between individual lesions within the same patients. WBMTB correlated with urinary serotonin (r = 0.51) and urinary and plasma 5-HIAA (r = 0.78 and 0.66). WBMTB also correlated with urinary norepinephrine, epinephrine, dopamine and plasma dopamine, but not with serum chromogranin A.
Tumour load per patient measured with F-18-dopa PET correlates with tumour markers of the serotonin and catecholamine pathway in urine and plasma in carcinoid patients, reflecting metabolic tumour activity.
|Number of pages||8|
|Journal||European Journal of Nuclear Medicine and Molecular Imaging|
|Publication status||Published - Oct-2011|
- F-18-dopa PET
- Carcinoid tumour
- Whole-body metabolic tumour burden
- NEUROENDOCRINE TUMORS
- CARBIDOPA PRETREATMENT
- CONSENSUS GUIDELINES
- SOLID TUMORS